Related Experiment Video

Updated: Mar 11, 2026

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.8K

[Research progress on pharmacotherapy of calcific aortic valve disease]

Miaomiao DU1, Gaigai Ma1, Yuping Shi2

  • 1Department of Cardiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.

Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences
|November 22, 2016
PubMed

Insights

Calcific aortic valve disease (CAVD) is a growing concern. Early pharmacotherapy, targeting inflammation and metabolism, shows promise in slowing CAVD progression and improving patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Calcific aortic valve disease (CAVD) is the leading cause of aortic valve replacement due to population aging.
  • CAVD is now understood as an active, multifactorial process, not just passive wear and tear.
  • Inflammation, calcium/phosphorus metabolism, and dyslipidemia are key contributors to CAVD.

Purpose of the Study:

  • To review recent advancements in pharmacotherapy for calcific aortic valve disease (CAVD).
  • To highlight the significance of early intervention in managing CAVD progression.
  • To explore potential therapeutic targets based on CAVD's underlying mechanisms.

Main Methods:

  • Review of recent histopathologic studies on CAVD.
  • Analysis of clinical trials investigating pharmacotherapies for CAVD.
  • Synthesis of research on statins, renin-angiotensin inhibitors, and anti-osteoporosis drugs in CAVD.

Main Results:

  • Pharmacotherapy trials have been informed by understanding CAVD's active, multifactorial nature.
  • Statin, renin-angiotensin inhibitors, and anti-osteoporosis drugs are actively being studied for CAVD.
  • Research indicates potential for pharmacologic intervention to slow CAVD progression.

Conclusions:

  • Early pharmacotherapy is crucial for managing calcific aortic valve disease (CAVD).
  • Targeting inflammation, lipid, and mineral metabolism offers therapeutic avenues for CAVD.
  • Continued research into pharmacotherapy is essential for improving quality of life in CAVD patients.

More Related Videos

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

4.7K
Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification08:55

Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification

Published on: November 20, 2017

10.3K

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
530
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
357
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
404
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K